Death

Safety-Focused E-scooter Provider Neuron Mobility Partners With Leading Canadian Road Safety Charity Traffic Injury Research Foundation (TIRF)

Monday, September 27, 2021 - 7:10pm

Neuron Mobility and leading Canadian road safety charity, the Traffic Injury Research Foundation, partner to promote e-scooter safety across Canada

Key Points: 
  • Neuron Mobility and leading Canadian road safety charity, the Traffic Injury Research Foundation, partner to promote e-scooter safety across Canada
    The partnership includes input on Neurons rider education materials, co-development of safety campaigns, and analysis of Neurons safety data
    TIRF works with governments and stakeholders across Canada to make roads safer and reduce road deaths and injuries.
  • As part of the partnership, TIRF is collaborating with Neuron and co-developing campaigns and activities to promote rider safety in Canada.
  • Zachary Wang, CEO of Neuron Mobility, said: Safety is at the heart of everything we do at Neuron so we are delighted to partner with TIRF, the leaders in road safety research in Canada.
  • For more information, visit: https://www.rideneuron.com
    Traffic Injury Research Foundation (TIRF) is an independent, charitable road safety research institute.

Statement Regarding Dissemination of COVID-19 Misinformation

Monday, September 27, 2021 - 7:00pm

Additionally, ABOG supports a recent American Board of Medical Specialties (ABMS) statement , which expresses concern regarding the serious public health effects of the persistent spread of misinformation regarding the COVID-19 virus.

Key Points: 
  • Additionally, ABOG supports a recent American Board of Medical Specialties (ABMS) statement , which expresses concern regarding the serious public health effects of the persistent spread of misinformation regarding the COVID-19 virus.
  • Patients rely on physicians to practice evidence-based medicine based on facts and scientific data.
  • These standards include:
    Providing intentional misinformation that may harm patients or public health does not meet these standards and may be grounds for adverse action on OB GYN certification status.
  • In addition, ABOG is alerted if an OB GYN is investigated for practice or professionalism violations by a state medical board.

Zeus Electric Chassis, Inc. to be Featured in Mobility Product Showcase at E Source Forum 2021

Monday, September 27, 2021 - 5:45pm

Zeus Electric Chassis, Inc. (Zeus) is one of six innovators in the mobility industry invited to participate in a Mobility Product Showcase.

Key Points: 
  • Zeus Electric Chassis, Inc. (Zeus) is one of six innovators in the mobility industry invited to participate in a Mobility Product Showcase.
  • Bill Brandt, Zeus Chief Revenue Officer, will present a short video about Zeus Electric Chassis and participate in an open Q&A session.
  • In the case of Zeus, E Source will join the CMC and the Sacramento Municipal Utility District (SMUD) to independently evaluate Zeus product performance.
  • Learn more about E Source at www.esource.com, and learn more about the forum at www.web.cvent.com/event/5accf916-e3e5-4742-9a54-91628c39fdfe/summary .

Top health organizations urge flu and COVID-19 vaccines to protect vulnerable, reduce burden on hospitals

Monday, September 27, 2021 - 5:21pm

According to the Centers for Disease Control and Prevention (CDC), the flu vaccine and the COVID-19 vaccines can be given in the same visit.

Key Points: 
  • According to the Centers for Disease Control and Prevention (CDC), the flu vaccine and the COVID-19 vaccines can be given in the same visit.
  • Both the flu vaccine and the COVID-19 vaccines are safe for people with chronic health conditions and are proven to provide the best protection against life-threatening complications from the two different viruses.
  • "We encourage everyone over six months old to get a flu shot and everyone over 12 years old get a COVID-19 vaccine.
  • "The flu is also significantly worse for people with diabetes and therefore, we strongly recommend getting both the flu and COVID-19 vaccines to protect your health if you are eligible.

Everside Health National Survey Shows Why More Than a Third of Americans Don't Plan to Get Flu Shot

Monday, September 27, 2021 - 4:08pm

"Even if you already received a COVID vaccine you still need your flu shot."

Key Points: 
  • "Even if you already received a COVID vaccine you still need your flu shot."
  • "Even if you already received a COVID vaccine you still need your flu shot," said Dr. Tobias Barker, Everside Health Chief Medical Officer.
  • Everside commissioned a national survey out of concern that some people may not be getting flu shots due to misinformation and misunderstandings about the risks.
  • Married people are also more likely to plan to get a flu shot this year than unmarried people (70% vs. 59%).

Global Animal Nutrition Organic Acids (Poultry, Swine, Ruminants, Aqua) Market to 2028 by Product, Species, Application, Delivery System, Region - ResearchAndMarkets.com

Monday, September 27, 2021 - 2:53pm

The "Global Animal Nutrition Organic Acids Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Animal Nutrition Organic Acids Market 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global animal nutrition organic acids market size is expected to reach USD 187.1 million by 2028.
  • The market is expected to expand at a CAGR of 6.5% from 2021 to 2028.
  • Organic acids are being increasingly used for feed preservation in commercial compound feeds and applications related to diets in pigs and poultry.

DGAP-News: Nantes University Hospital Doses First Patients with Eckert & Ziegler's Novel Ga-68 Imaging Agent PENTIXAFOR

Monday, September 27, 2021 - 2:19pm

The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas.

Key Points: 
  • The Centre Hospitalier Universitaire de Nantes (CHU), the French university hospital serving the greater Nantes/Saint-Nazaire metropolitan area, has started to dose first patients with PENTIXAFOR, an innovative imaging compound for the initial staging of cancer patients with symptomatic multiple myelomas.
  • To investigate the potential of PENTIXAFOR the CHU will recruit, on its own account, up to 45 patients in a so-called investigator-initiated study (ISS).
  • Given the potential of PENTIXAFOR for improved patient stratification, academic groups like CHU have decided to move ahead on their own and to test PENTIXAFOR right away.
  • To speed up the PENTIXAFOR marketing authorization, Eckert & Ziegler closely cooperates with such initiatives and supports them where feasible.

Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

Monday, September 27, 2021 - 1:30pm

CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans to initiate Part B of the MOMENTUM study (Study 5051-201), in the fourth quarter. MOMENTUM is a global trial investigating the use of SRP-5051, the Company’s next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.

Key Points: 
  • MOMENTUM is a global trial investigating the use of SRP-5051, the Companys next-generation peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
  • The study will enroll between 20-40 patients between ages 7 to 21 amenable to exon 51 skipping who are nave to SRP-5051.
  • SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping.
  • EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

StoneMor Inc. Announces Receipt of Letter Inviting Discussions Regarding Strategic Alternatives

Monday, September 27, 2021 - 1:45pm

Axar has engaged Schulte Roth & Zabel LLP as its legal advisor and stated in the Letter that it would engage a financial advisor at the appropriate time.

Key Points: 
  • Axar has engaged Schulte Roth & Zabel LLP as its legal advisor and stated in the Letter that it would engage a financial advisor at the appropriate time.
  • According to the Letter, Axar expects that any such discussions would be conducted with a special committee of the Board, assisted by financial and legal advisors it engages.
  • The Conflicts Committee intends to retain independent legal and financial advisors to assist in such discussions.
  • Certain statements contained in this press release, including, but not limited to, information regarding actions of the Conflicts Committee, are forward-looking statements.

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

Monday, September 27, 2021 - 1:30pm

This latest study follows an earlier safety and dose-escalation crossover study conducted by Grace, which reported encouraging results.

Key Points: 
  • This latest study follows an earlier safety and dose-escalation crossover study conducted by Grace, which reported encouraging results.
  • Moreover, it could provide a more convenient dosing schedule that would be easier to administer to patients who are unconscious.
  • The PK bridging study is a single center, randomized, two-period crossover study in 50 healthy subjects.
  • Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.